Objective: To investigate the influence of the expression profile of mammalian target of rapamycin-related proteins on the development of interstitial fibrosis after kidney transplantation. Methods: Immunohistochemical staining was carried out to evaluate the expression of five mammalian target of rapamycin-related proteins (phosphorylated-Akt, Ras homolog enriched in brain, phosphorylated-mammalian target of rapamycin, phosphorylated-p70 ribosomal S6 kinase and phosphorylated-4E binding protein 1) in graft biopsy specimens obtained from 77 patients at 3 months after kidney transplantation. The change of the estimated glomerular filtration rate and the change of the fibrosis index (defined as the change in the percent area of fibrosis on Masson's trichrome-stained sections of biopsy specimens) from 3 months to 3 years after kidney transplantation were determined. Results: There was a significant correlation between change of the estimated glomerular filtration and change of the fibrosis index in the 77 patients. Univariate analysis identified expression of phosphorylated-Akt, phosphorylated-mammalian target of rapamycin and phosphorylated-p70 ribosomal S6 kinase, as well as donor type and pre-transplant dialysis duration, as significant predictors of a change of the fibrosis index >10%. However, only phosphorylated-mammalian target of rapamycin expression, phosphorylated-p70 ribosomal S6 kinase expression and donor type were independently associated with a change of the fibrosis index >10% according to multivariate analysis. Conclusions: These findings suggest that mammalian target of rapamycin-related proteins are involved in the development of interstitial fibrosis after kidney transplantation.
Introduction
Progress in immunosuppressive therapy for patients undergoing KTx has significantly reduced the incidence of acute rejection, resulting in a marked improvement of early graft survival. Therefore, long-term renal graft survival has attracted considerable attention in recent years. 1 Although histological evaluation of renal graft biopsies is currently regarded as essential for assessment of graft function, it remains difficult to predict long-term graft survival from routine graft biopsy findings. Accordingly, it is necessary to identify molecular markers associated with long-term graft function that can be used to predict renal graft survival.
The major pathological feature of chronic renal failure as a result of various kidney diseases is IF, which is characterized by abnormal accumulation of the extracellular matrix in the kidneys and is closely correlated with the severity of renal dysfunction, representing the final common pathway for many chronic progressive kidney diseases. 2, 3 Several studies have also shown a negative impact of IF on kidney allograft function. 4, 5 For example, Pape et al. reported that quantitative measurement of IF by picrosirius red staining was a useful indicator of long-term graft function. 4 The introduction of allograft biopsy protocols has led to clarification of the natural history of IF after KTx, revealing that IF occurs in renal grafts, even those with stable function. 6 Because development of IF in the kidneys is a complex process that involves multiple cell types and numerous mediators, the detailed molecular mechanisms are still largely unclear. mTOR is an evolutionally conserved multiprotein complex, including mTORC1 and mTORC2, which is a potential downstream effector of Akt in various pathophysiological processes. mTORC1 is activated through Akt-mediated inhibition of the tuberous sclerosis complex and mTORC2 phosphorylates various substrates, including Akt. 7 Activated mTOR directly phosphorylates p70S6K and 4E-BP1, resulting in enhanced synthesis of proteins involved in a wide variety of cellular functions, such as proliferation, differentiation, metabolism, migration and angiogenesis. [8] [9] [10] In recent years, both experimental and clinical studies have shown that signaling through the mTOR pathway is an important modulator of renal disease, as mTOR activation is accompanied by impairment of podocyte function and is uniformly observed in most chronic kidney diseases. [11] [12] [13] It has been well documented that mTOR inhibitor therapy ameliorates key changes associated with progressive renal dysfunction in chronic kidney disease, such as glomerular hypertrophy, intrarenal inflammation and IF. 11, 14, 15 In the present study, we evaluated the expression of major proteins mediating mTOR signaling by immunohistochemical staining of renal graft biopsy specimens, and we analyzed the relationships of these proteins with IF to find markers for early detection of interstitial fibrosis after KTx.
Methods

Patients
Between 2000 and 2012, 104 KTx procedures were carried out at Kobe University Hospital, Kobe, Japan (Fig. 1) . We excluded three patients with an eGFR <30 mL/min at 3 months after KTx. At 3 months and 3 years after KTx, core needle biopsy of the grafted kidney was carried out with a biopsy gun (18 G; CR Bard, Covington, GA, USA) under ultrasonographic guidance in 95 patients who gave informed consent. Three of the 95 patients were excluded from the present study because insufficient tissue was obtained at either 3 months or 3 years after KTx. Biopsy specimens of the remaining 92 patients were evaluated by two observers in a blinded fashion according to the 2013 Banff working classification. 16 A total of 15 patients were also excluded from this study because of rejection or recurrence of the primary disease during the 3-year period after KTx. Among the 12 patients with rejection, 10 patients developed clinical rejection, and an episode biopsy gave a diagnosis of acute T cellmediated rejection (n = 8) or acute antibody-mediated rejection (n = 2), whereas subclinical acute T cell-mediated rejection was detected by protocol biopsy in two patients. Among the remaining 77 patients included in this study, two patients had a very low positive donor-specific antibody titer before KTx, but neither of them developed clinical rejection or showed evidence of acute or chronic rejection on protocol biopsy. The protocol of the present study was approved by the research ethics committee of Kobe University Hospital, and informed consent was obtained from each patient before enrollment.
Immunosuppressive therapy involved intravenous infusion of either CsA or Tac for 3 or mL, 5-7 ng/mL and 5 ng/mL from 2009. Patients were also treated with mycophenolate mofetil (30 mg/kg), methylprednisolone (500 mg bolus on day 0, tapering to 0.1 mg/kg at 4 weeks after KTx) and basiliximab (20 mg/kg on days 0 and 4).
Immunohistochemistry
Immunohistochemical staining was carried out, as reported previously, using the following anti-human antibodies: antiphosphorylated-Akt (Ser473; Cell Signaling, Beverly, MA, USA) at a 1:100 dilution; anti-Rheb (Abcam, Cambridge, UK) at a 1:200 dilution; anti-p-mTOR (Ser2448; Cell Signaling) at a 1:100 dilution; anti-p-4EBP1 (Thr37/46; Cell Signaling) at a 1:200 dilution; and anti-p-p70S6K (Thr389; Cell Signaling) at a 1:200 dilution. 17 Staining was evaluated by two independent investigators who were blinded to the clinicopathological data. Differences were resolved by consensus and/or by consultation with a third observer who was an expert in immunohistochemical pathology. The percent area of the biopsy specimen stained by each antibody was scored as follows: 0, <5%; 1, 5-15%; 2, 16-30%; and 3, >30%. To simplify statistical analysis, scores of 0 or 1 and scores of 2 or 3 were classified as weak expression or strong expression, respectively.
Evaluation of renal graft function and fibrosis
Renal function was assessed by calculating the eGFR with adjustment for diet according to the modified equation for Japanese patients proposed by the Japanese Society of Nephrology (eGFR = 194 9 serum creatinine mg/ dL À1.094 9 age À0.287 9 0.739 [females]). As an index of the decline in graft function, DeGFR was calculated as the change of eGFR from 3 months to 3 years after KTx (DeGFR = eGFR at 3 years after KTx -eGFR at 3 months after KTx). The FI was calculated by imaging analysis, as described previously. 17 Briefly, sections of biopsy specimens obtained at 3 months and 3 years after KTx were stained with Masson's trichrome stain and were examined under a microscope with an attached video camera (Keyence America, Nashville, TN, USA). Using the 910 objective, images were obtained along the longitudinal axis of the biopsy specimen that included all of the available cortex without overlapping, after which digitized images were analyzed with Image J software (National Institutes of Health, Bethesda, MD, USA). A blue color threshold macro was used to measure the area of fibrotic interstitium stained blue by Masson's trichrome. The FI was determined as the percentage of the total tissue area in the biopsy sections occupied by fibrotic interstitium, and DFI was calculated as the change of the FI from 3 months to 3 years after KTx (DFI = FI at 3 years after KTx À FI at 3 months after KTx). The FI was determined three times, and the mean value was calculated for use in the present study. DFI >10% was defined as indicating progression of renal graft fibrosis, whereas DFI ≤10% was defined as a stable graft.
Statistical analysis
All statistical analyses were carried out with StatView 5.0 software (Abacus Concepts, Berkeley, CA, USA), and a Pvalue of <0.05 was considered to show a significant difference. Pearson's correlation coefficient analysis was used to evaluate the relationship between DeGFR and DFI. Comparison of DFI between groups with weak and strong expression of each of the five markers was carried out by the non-parametric Mann-Whitney U-test. Forward stepwise logistic regression analysis was carried out to determine the association of various parameters with a DFI >10%. The v
2
-test was used to analyze the association between the number of risk factors and DFI.
Results Table 1 summarizes the characteristics of the 77 patients investigated in the present study. Immunohistochemical staining of graft biopsy specimens obtained at 3 months after KTx revealed expression of p-Akt, Rheb, p-mTOR, pp70S6K and p-4E-BP1 mainly in the cytoplasm of cells in the proximal and distal renal tubules. There were no marked differences in the pattern of expression of these five markers between proximal and distal tubular cells. Slight staining of the glomeruli was occasionally observed, but glomerular staining was limited to the epithelium of Bowman's capsule and the mesangial cells. No staining of the periglomerular and peritubular interstitium was detected. As positive staining was largely confined to either proximal or distal tubular cells, we evaluated the cytoplasmic staining of tubular cells when scoring all five mTOR-related proteins. Typical findings obtained by immunohistochemical staining are shown in Figure 2 . In the 62 patients who received living donor kidneys, expression of all five mTOR-related proteins was extremely low in pre-transplant donor kidney biopsy specimens, and was significantly lower than at 3 months after KTx (Fig. 3) .
Mean eGFR was 61.1 and 56.3 mL/min at 3 months and 3 years after KTx, respectively, whereas the mean FI of the renal grafts was 9.9 and 18.0% at 3 months and 3 years, respectively. Both eGFR and FI showed significant differences between 3 months and 3 years after KTx. In addition, there was a significant correlation between DeGFR and DFI in the 77 patients (Fig. 4) . We assessed DFI according to the expression of mTORrelated proteins. As shown in Figure 5 , DFI was larger in patients with strong expression of any of the five proteins than in patients with weak expression. There were significant differences of DFI between the patients with strong or weak expression of p-Akt, Rheb, p-mTOR and p-p70S6K. Table 2 shows the results of univariate and multivariate analyses that evaluated the relationships between a DFI >10% and several parameters, including expression of mTORrelated proteins. In addition to donor type and the pre-transplant dialysis duration, univariate analysis identified expression of p-Akt, p-mTOR and p-p70S6K as significant predictors of a DFI >10%. Among these five significant predictors identified by univariate analysis, only p-mTOR expression, p-p70S6K expression and donor type were independently associated with a DFI >10% according to multivariate analysis. When patients were classified into three groups according to the number of independent risk factors for DFI >10% identified by multivariate analysis, only one out of 33 patients (3.0%) with no risk factors had a DFI >10% versus four out of 19 patients (21.1%) with one risk factor and 19 out of 25 patients (76.0%) with two or three risk factors. There were significant difference in the percentage of patients with a DFI >10% among these three groups (Table 3) . 
Discussion
IF is currently considered to be the factor most closely correlated with loss of graft function after KTx, but the extent of IF in graft biopsy specimens obtained soon after KTx is not a good predictor of long-term allograft function. 6, 18 The mTOR signaling pathway is thought to play an important role in promoting IF in kidney allografts. Therefore, we evaluated the expression of major mTOR-related proteins in renal graft biopsy specimens obtained soon after KTx, and investigated whether any of these proteins could be used as predictors of the progression of IF.
In the present study, immunohistochemical staining of kidney graft biopsy specimens obtained 3 months after KTx showed uniform expression of all five mTOR signaling pathway proteins, mainly by cells of the proximal and distal renal tubules, in contrast to weak expression of these molecules in pre-transplant biopsy specimens. Li and Zhang have also reported upregulation of p-mTOR, p-p70S6K and p-4E-BP1 expression in the glomerular and tubular epithelium after KTx. 19 Furthermore, we found that the expression of these five mTOR-related proteins showed a similar pattern at 3 years after KTx to that at 3 months (data not shown). Considering these results, similar activation of mTOR signaling to that in chronic kidney disease might occur in renal allografts from the early period after KTx. We evaluated the progression of IF by Masson's trichrome staining of graft biopsy specimens, and found that IF was significantly more advanced at 3 years than 3 months after KTx. In addition, there was a significant correlation between the changes of IF and eGFR from 3 months to 3 years after KTx. These findings suggest that progression of IF has a crucial impact on the decline of graft function. Therefore, we assessed the relationship between expression of mTOR-associated proteins and the change of IF from 3 months to 3 years after KTx. We found that progression of IF was significantly greater in the patients with strong expression of four of the five mTOR-related proteins (except for p-4E-BP1) than in those with weak expression of these proteins. To our knowledge, this is the first clear evidence of the progression of allograft fibrosis in patients with overactivation of the mTOR signaling pathway soon after KTx.
We also investigated the usefulness of mTOR signaling markers for predicting the progression of IF after KTx. Logistic regression analysis of various clinical parameters and expression of five mTOR-related proteins showed that an increase of IF by >10% between 3 months and 3 years after KTx was independently associated with high expression of pmTOR or p-p70S6K, in addition to use of a deceased donor graft. However, none of the variables examined was an independent risk factor for the reduction of eGFR (data not shown).
The mTOR pathway plays an important role in renal repair and homeostasis through regulation of cell growth and proliferation. Lieberthal et al. showed that mTOR activity is low or absent in the normal kidney, but is markedly increased by ischemia-reperfusion injury. In addition, inhibition of mTOR by rapamycin has been reported to delay recovery of renal function and tissue repair. 20 Conversely, several studies have shown that mTOR pathway overactivation stimulates fibroblast proliferation and increases the expression of profibrotic cytokines, such as transforming growth factor-b1, thus mediating tubulointerstitial fibrosis. [21] [22] [23] mTOR plays a central role in signal transduction through both mTORC1 and mTORC2 in numerous of pathological conditions, whereas p70S6K and 4E-BP1 are two major downstream effectors regulated by mTOR. Therefore, it might be considered difficult to explain our finding that p-4E-BP1 was not a useful predictor of IF after KTx. However, several studies have already provided evidence for a differential impact of p-p70S6K and p-4E-BP1 on IF in renal allografts. For example, changes of mTOR activity have a stronger influence on p70S6K phosphorylation in kidney fibroblasts than changes of 4E-BP1 in a rat model, whereas changes in the expression of p-p70S6K (but not p-4E-BP1) after transforming growth factor-b1 stimulation are proportional to the changes of p-mTOR expression. 24 It would be useful to be able to precisely predict the risk of renal IF in the early period after KTx by combined assessment of risk factors, as this would allow individualization of follow up and immunosuppressive therapy.
Therefore, based on the three independent risk factors for IF identified by our multivariate analysis, the 77 patients in the present study were classified into three groups (zero risk factors, one risk factor and two or three risk factors), and differences in the percentage of patients with progression of IF were compared. There were significant differences among the three groups, suggesting that assessment of these three risk factors (increased expression of p-mTOR, increased expression of p-p70S6K and deceased donor graft) might be useful for developing a novel system to predict progression of IF after KTx.
There were several limitations to the present study. First, it was a retrospective analysis of a small number of patients, and the follow-up period was not long enough to draw definite conclusions about the prognosis for graft function. Second, allograft function was only evaluated from the eGFR, because data on creatinine clearance obtained using 24-h urine samples were not available. Third, the immunosuppression protocol changed slightly during the study period, which might have influenced the outcomes. However, there were no significant differences of clinical data (including eGFR) at 3 months and 3 years after KTx between patients receiving the different immunosuppression protocols, and there was also no significant difference of the change in eGFR from 3 months to 3 years after KTx (data not shown). Fourth, we also analyzed the outcomes in patients with DFI >10% stratified according to the change of IFTA category from 3 months to 3 years after KTx. However, univariate and multivariate analyses did not reveal any specific impact of the IFTA category, probably because of the small number of patients in each group. Fifth, the 2011 Banff meeting report mentions that 1-year biopsy specimens show greater expression of profibrotic genes than early post-KTx specimens, which tend to reflect prior injury. 25 However, we could not obtain such data for all 77 patients, because we carried out 1-year protocol biopsy in a limited number of participants. Sixth, the five mTOR pathway proteins examined in the present study were selected subjectively rather than scientifically, and staining of each protein was evaluated semiquantitatively by just two investigators, which makes it difficult to standardize our approach considering the reproducibility of this approach. Finally, several recent studies have identified novel effects of mTOR signaling in various pathological conditions associated with renal IF, including activation of macrophages and fibroblasts, suggesting that the prognostic influence of such effects should be investigated in the future.
In conclusion, a prospective study that also assesses other potential molecular markers for the development of IF will be required to confirm our findings. However, measurement of the expression of mTOR-related proteins, especially p-mTOR and p-p70S6K, soon after KTx might be helpful for predicting long-term graft function, thus facilitating early intervention and optimal management of transplant patients.
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